Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response

Abstract Objective Many patients with melanoma treated with immune checkpoint inhibitors (ICIs) do not derive response. Preclinical and retrospective studies identified that inhibition of the cyclooxygenase (COX) pathway may improve response to ICI treatment. Methods This prospective single site pha...

Full description

Bibliographic Details

Published in:	BJC Reports
Main Authors:	Zoe Quandt, Saya Jacob, Muhammad Zaki Hidayatullah Fadlullah, Chaorong Wu, Clinton Wu, Laura Huppert, Lauren S. Levine, Paula Sison, Katy K. Tsai, Melissa Chow, Jee Hye Kang, Jimmy Hwang, James C. Lee, Ariel Oglesby, Jessica Venegas, Ben J. Brintz, Aik Choon Tan, Mark S. Anderson, Michael D. Rosenblum, Arabella Young, Adil I. Daud
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-06-01
Online Access:	https://doi.org/10.1038/s44276-024-00057-7